Abstract Library

#4645 Radio-guided surgery in use for treatment of early relapse in small intestine neuroendocrine tumours

Introduction: Surgery is the only definitive therapy for neuroendocrine tumours (NET). In number of small intestine NET first symptom is ileus or perforation, lifesaving surgical procedures applied. Such cases have significant risk of recurrence.

Conference:

Presenting Author: Hajac �

Authors: Hajac L, Szewczyk K, Piwkowski P, Chowaniec Z, Mazurak J,

Keywords: radio guided surgery, Neuroendocrine tumour, early relapse,

#4616 Clinical characterisation of patients with familial midgut neuroendocrine tumours (FM-NETs) based on a comparison with the large population-based GTE/RENATEN cohort

Introduction: The clinical specificities of FM-NET have been poorly described.

Conference:

Presenting Author: Hunaut T

Authors: Hunaut T, Hercent A, Walter T, Buecher B, Lepage C,

Keywords: Small intestine neuroendocrine tumour, Familial carcinoid tumour,

#4587 Exploring the splicing landscape to identify survival-related biomarkers in small intestine neuroendocrine neoplasms

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) is challenging due to their rarity and complexity. While transcriptomic subtypes have been identified, the mechanisms behind their progression are still unclear. The process of RNA splicing is often altered in cancer, and our group has described that such dysregulation is also present in various NENs.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, García Vioque V, Pedraza-Arévalo S, Hernando Cubero J, García A,

Keywords: small intestine neuroendocrine tumour, splicing, biomarker, survival, ki-67, RNA,

#4477 Stable tumoural response to stereotactic body radiotherapy in well-differentiated metastatic small intestine neuroendocrine tumour

Introduction: Over half of patients with Neuroendocrine tumours (NET) have unresectable or metastatic disease. SSA y PRRT are successful targeted therapy to symptoms relief and stabilise disease. Otherwise, there are emerging options of radiotherapy including hypofractionation or stereotactic body radiotherapy. The clinical evidence of radiotherapy in NEN is scarce, and there is limited published data.

Conference:

Presenting Author: Florez A

Authors: Sanabria D, Florez A,

Keywords: Neuroendocrine, Tumour, metastatic,

#4408 Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,